XML 45 R21.htm IDEA: XBRL DOCUMENT

Segment Reporting

12 Months Ended

Jun. 30, 2024

Note 15. Segment Reporting

Description of segments and principal activities

The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. The executive management uses the measure of profit and loss to assess segment performance.

Management considers the business from both a product and a geographic perspective and has identified two reportable segments:

Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia and United States.

Hyper-immune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world.

Financial breakdown

The segment information for the reportable segments for the year ended June 30, 2024 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2024	A$			A$			A$			A$
Hyper-immune products revenue		-			4,902,865			-			4,902,865
Cost of sales of goods		-			(1,566,068	)		-			(1,566,068	)
Gross profit		-			3,336,797			-			3,336,797
Other income		3,364,439			43,760			-			3,408,199
Fair value gains/(losses)to financial assets		-			-			(557,676	)		(557,676	)
Net foreign exchange gains/(losses)		-			-			(27,603	)		(27,603	)
Movement in inventory provision		-			-			-			-
General and administrative expenses		(460,251	)		(3,565	)		(4,091,910	)		(4,555,726	)
Research and development expenses		(5,375,461	)		-			-			(5,375,461	)
Selling and marketing expenses		-			(2,029,648	)		-			(2,029,648	)
Operating profit/(loss)		(2,471,273	)		1,347,344			(4,667,184	)		(5,801,118	)
Finance income		-			-			327,756			327,756
Finance costs		-			-			(7,576	)		(7,576	)
Share of loss from associates		-			-			(1,456,019	)		(1,456,019	)
Income tax expense		-			-			-			-
Profit/(loss) for the year		(2,471,273	)		1,347,344			(5,813,028	)		(6,936,957	)
Assets
Segment assets		768,370			2,845,096			11,936,503			15,549,969
Total assets		768,370			2,845,096			11,936,503			15,549,969
Liabilities
Segment liabilities		604,018			206,524			2,029,983			2,840,525
Total liabilities		604,018			206,524			2,029,983			2,840,525

The segment information for the reportable segments for the year ended June 30, 2023 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2023	A$			A$			A$			A$
Hyper-immune products revenue		-			1,804,705			-			1,804,705
Cost of sales of goods		-			(495,558	)		-			(495,558	)
Gross profit		-			1,309,147			-			1,309,147
Other income		2,551,813			39,685			-			2,591,498
Fair value gains/(losses)to financial assets		-			-			(523,666	)		(523,666	)
Net foreign exchange gains/(losses)		-			-			363,724			363,724
Movement in inventory provision		-			430,932			-			430,932
General and administrative expenses		(460,251	)		26,256			(3,786,910	)		(4,220,905	)
Research and development expenses		(2,592,145	)		-			-			(2,592,145	)
Selling and marketing expenses		-			(927,423	)		-			(927,423	)
Operating profit/(loss)		(500,583	)		878,597			(3,946,852	)		(3,568,838	)
Finance income		-			-			116,323			116,323
Finance costs		-			-			(9,652	)		(9,652	)
Share of loss from associates		-			-			(324,340	)		(324,340	)
Income tax expense		-			-			-			-
Profit/(loss) for the year		(500,583	)		878,597			(4,164,521	)		(3,786,507	)
Assets
Segment assets		398,391			2,078,643			19,511,148			21,988,182
Total assets		398,391			2,078,643			19,511,148			21,988,182
Liabilities
Segment liabilities		604,018			206,524			1,560,804			2,371,346
Total liabilities		604,018			206,524			1,560,804			2,371,346

The segment information for the reportable segments for the year ended June 30, 2022 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2022	A$			A$			A$			A$
Hyper-immune products revenue		-			765,193			-			765,193
Cost of sales of goods		-			(241,691	)		-			(241,691	)
Gross profit		-			523,502			-			523,502
Other income		933,140			24,585			-			957,725
Net foreign exchange gains/(losses)		-			-			247,558			247,558
General and administrative expenses		-			(164,087	)		(3,360,301	)		(3,524,388	)
Research and development expenses		(657,715	)		-			-			(657,715	)
Selling and marketing expenses		-			(416,537	)		-			(416,537	)
Operating profit/(loss)		275,425			(32,537	)		(3,112,743	)		(2,869,855	)
Finance income		-			-			21,785			21,785
Finance costs		-			-			(6,184	)		(6,184	)
Profit/(loss) for the year		275,425			(32,537	)		(3,097,142	)		(2,854,254	)

Assets
Segment assets		257,500			1,688,910			22,909,414			24,855,824
Total assets		257,500			1,688,910			22,909,414			24,855,824

Liabilities
Segment liabilities		7,053			150,151			1,521,219			1,678,423
Total liabilities		7,053			150,151			1,521,219			1,678,423

Information on geographical regions:

The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions:

	Travelan						Protectyn
	Australia		United States		Canada		Australia		Total
2024	A$		A$		A$		A$		A$
Hyper-immune products revenue		3,702,876		1,075,614		80,888		43,487		4,902,865
Revenue from external customers		3,702,876		1,075,614		80,888		43,487		4,902,865

	Travelan						Protectyn
	Australia		United States		Canada		Australia		Total
2023	A$		A$		A$		A$		A$
Hyper-immune products revenue		1,100,725		642,819		1,201		59,960		1,804,705
Revenue from external customers		1,100,725		642,819		1,201		59,960		1,804,705

	Travelan						Protectyn
	Australia		United States		Canada		Australia		Total
2022	A$		A$		A$		A$		A$
Hyper-immune products revenue		143,378		501,228		63,172		57,415		765,193
Revenue from external customers		143,378		501,228		63,172		57,415		765,193

Information on major customers:

During the years ended June 30, 2024, 2023 and 2022, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues:

	2024 A$		2023 A$		2022 A$
Customer A		2,308,425		626,107		99,792
Customer B		957,076		-		-
Customer C		842,173		223,504		34,020
Customer D		552,509		236,437		-
Customer E		-		465,614		253,803
Customer F		-		-		263,137
		4,660,183		1,551,662		650,752